Conclusion: Supplementation of healthy middle-aged and senior adults with lactononadecapeptide tablets for 12 weeks improved cognitive abilities, including attention and speed of information processing. There were no adverse events attributed to lactononadecpeptide tablets, and no marked changes were observed in the blood and urinary analysis. There were no significant improvement in these scores in the placebo group. There were a statistically significant improvement in the social functioning, vitality and mental component summary of the SF-36 after 12 weeks intake of lactononadecapeptide tablets.
Results: Changes in the number of correct answers on the Uchida-Kraepelin test from baseline to 12 weeks were significantly different between the test and placebo groups. Cognitive function and quality of life (QOL) were measured using the Mini-Mental State Examination (MMSE), the Uchida-Kraepelin test, the recognition memory test and SF-36, at baseline and after 12 weeks of supplementation. Subjects were randomly divided into test and placebo groups before ingesting 2.1 mg/day lactononadecapeptide or the equivalent. Methods: We conducted a randomized, double-blind, placebo-controlled trial in 72 healthy Japanese subjects. Serviciul gratuit de traducere online al Reverso, traduce textele dumneavoastr din englez i francez, spaniol, italian, german, rus, portughez.
Objectives: To evaluate the effect of tablets containing lactononadecapeptide (NIPPLTQTPV-VVPPFLQPE) on cognitive function in healthy middle-aged and senior adults.
